Eileen, I think this paragraph is most important. This person,...

Eileen, I think this paragraph is most important. This person, whoever it is, already understands that there will be additional positive results, from already compromised persons. If this is the result, I am sure that there will be a lot of happy medico’s, because it increases the probability of even higher positive results from less compromised persons, or first treatment persons.
I don’t see this as a failure. Who is this person. What is the total sales for the last three days as a percentage of soi.
This is a spec stock. It could be AHZ or it could be NEU.
Either way, investigate everything, and don’t get caught out, up or down.

- from the “email”
While I may be wrong, I believe we're only going to see marginal gains in the current MAST study as they dose escalate. IMO, this will largely be due to the large number immuno-compromised patients in the MAST study. We'll certainly pickup additional CRs, PRs and SDs, here and there, at higher doses. These will be mainly from relatively healthy patients. I believe the next trial update(s) will likely fall short in terms of the wow factor many retail investors are looking for